Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
Tevogen Bio (TVGN) has commissioned Databricks to accelerate the development of PredicTcell, their proprietary AI-driven target prediction model for precision immunotherapy. The collaboration will leverage Databricks' expertise in data engineering and AI systems to enhance PredicTcell's capabilities in modeling immunologically active HLA+ peptide complexes and TCR engagement prediction.
The partnership focuses on developing two foundational models based on Tevogen's ExacTcell™ platform: predicting immunologically active peptides through machine learning and creating a predictive T cell receptor binding model. This marks the third pillar of Tevogen.AI, alongside Microsoft Research providing digital infrastructure and AI expertise, while Tevogen Bio leads clinical and immunological science strategy.
Tevogen Bio (TVGN) ha incaricato Databricks di accelerare lo sviluppo di PredicTcell, il loro modello proprietario di previsione basato sull'intelligenza artificiale per l'immunoterapia di precisione. La collaborazione sfrutterà l'esperienza di Databricks nell'ingegneria dei dati e nei sistemi di AI per potenziare le capacità di PredicTcell nella modellazione dei complessi peptidici HLA+ immunologicamente attivi e nella previsione dell'ingaggio del recettore TCR.
La partnership si concentra sullo sviluppo di due modelli fondamentali basati sulla piattaforma ExacTcell™ di Tevogen: la previsione di peptidi immunologicamente attivi tramite apprendimento automatico e la creazione di un modello predittivo per il legame del recettore delle cellule T. Questo rappresenta il terzo pilastro di Tevogen.AI, affiancando Microsoft Research che fornisce infrastrutture digitali e competenze in AI, mentre Tevogen Bio guida la strategia clinica e immunologica.
Tevogen Bio (TVGN) ha encargado a Databricks acelerar el desarrollo de PredicTcell, su modelo propietario de predicción impulsado por IA para inmunoterapia de precisión. La colaboración aprovechará la experiencia de Databricks en ingeniería de datos y sistemas de IA para mejorar las capacidades de PredicTcell en la modelación de complejos peptídicos HLA+ inmunológicamente activos y la predicción del compromiso del receptor TCR.
La asociación se centra en desarrollar dos modelos fundamentales basados en la plataforma ExacTcell™ de Tevogen: predecir péptidos inmunológicamente activos mediante aprendizaje automático y crear un modelo predictivo de unión del receptor de células T. Esto marca el tercer pilar de Tevogen.AI, junto con Microsoft Research que proporciona infraestructura digital y experiencia en IA, mientras que Tevogen Bio lidera la estrategia clínica e inmunológica.
Tevogen Bio (TVGN)는 정밀 면역치료를 위한 독자적인 AI 기반 표적 예측 모델인 PredicTcell 개발 가속화를 위해 Databricks와 협력했습니다. 이번 협력은 Databricks의 데이터 엔지니어링 및 AI 시스템 전문성을 활용하여 PredicTcell의 면역 활성 HLA+ 펩타이드 복합체 모델링과 TCR 결합 예측 능력을 향상시키는 데 중점을 둡니다.
이 파트너십은 Tevogen의 ExacTcell™ 플랫폼을 기반으로 두 가지 기본 모델 개발에 집중합니다: 기계 학습을 통한 면역 활성 펩타이드 예측과 T 세포 수용체 결합 예측 모델 생성입니다. 이는 디지털 인프라와 AI 전문성을 제공하는 Microsoft Research와 임상 및 면역 과학 전략을 주도하는 Tevogen Bio와 함께하는 Tevogen.AI의 세 번째 핵심 축입니다.
Tevogen Bio (TVGN) a mandaté Databricks pour accélérer le développement de PredicTcell, leur modèle propriétaire de prédiction ciblée basé sur l'IA pour l'immunothérapie de précision. Cette collaboration exploitera l'expertise de Databricks en ingénierie des données et systèmes d'IA afin d'améliorer les capacités de PredicTcell dans la modélisation des complexes peptidiques HLA+ immunologiquement actifs et la prédiction de l'engagement du récepteur TCR.
Le partenariat vise à développer deux modèles fondamentaux basés sur la plateforme ExacTcell™ de Tevogen : la prédiction des peptides immunologiquement actifs via l'apprentissage automatique et la création d'un modèle prédictif de liaison des récepteurs des cellules T. Cela constitue le troisième pilier de Tevogen.AI, aux côtés de Microsoft Research qui fournit l'infrastructure numérique et l'expertise en IA, tandis que Tevogen Bio dirige la stratégie clinique et immunologique.
Tevogen Bio (TVGN) hat Databricks beauftragt, die Entwicklung von PredicTcell, ihrem proprietären KI-gestützten Zielvorhersagemodell für die präzisionsmedizinische Immuntherapie, zu beschleunigen. Die Zusammenarbeit nutzt Databricks' Expertise in Datenengineering und KI-Systemen, um die Fähigkeiten von PredicTcell bei der Modellierung immunologisch aktiver HLA+ Peptid-Komplexe und der Vorhersage der TCR-Bindung zu verbessern.
Die Partnerschaft konzentriert sich auf die Entwicklung von zwei grundlegenden Modellen auf Basis der ExacTcell™ Plattform von Tevogen: die Vorhersage immunologisch aktiver Peptide mittels maschinellen Lernens und die Erstellung eines prädiktiven Modells für die Bindung von T-Zell-Rezeptoren. Dies stellt die dritte Säule von Tevogen.AI dar, neben Microsoft Research, das digitale Infrastruktur und KI-Expertise bereitstellt, während Tevogen Bio die klinische und immunologische Strategie leitet.
- Strategic partnership with Databricks strengthens AI capabilities
- Development of proprietary AI-driven prediction technology
- Expansion of technology infrastructure through multiple industry leaders
- None.
WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the commission of Databricks, Inc., a leader in data, analytics and artificial intelligence (AI), with an aim to accelerate the development of PredicTcell, the Company’s proprietary AI-driven target prediction model for precision immunotherapy.
Databricks will provide a dedicated data engineering team and its expertise in building, scaling, and governing data and AI systems. This support should advance PredicTcell's capabilities in modeling immunologically active HLA+ peptide complexes and predicting T cell receptor (TCR) engagement with those complexes. The efforts will be directed to bring two foundational models to bear based on the company’s revolutionary ExacTcell™ platform: predicting immunologically active peptides through machine learning and developing a predictive T cell receptor binding model.
This announcement marks the third foundational support pillar for Tevogen.AI, the Company’s AI initiative which aims to transform precision medicine:
- Microsoft Research – contributing digital infrastructure, scientific research, and AI expertise.
- Databricks – data infrastructure, engineering, and analytics to enable AI model development.
- Tevogen Bio – providing clinical and immunological science and strategic leadership.
About Tevogen
Tevogen is a healthcare company dedicated to delivering innovative and affordable solutions for large patient populations. The company operates across three strategic pillars: Tevogen Bio, advancing off-the-shelf, genetically unmodified precision T cell therapies; Tevogen.AI, leveraging artificial intelligence to accelerate drug discovery and optimize healthcare delivery; and Tevogen Generics, committed to increasing access to high-quality essential medicines. Tevogen owns all key intellectual property and is led by a highly experienced team of scientific, AI, and financial leaders with deep expertise in drug development and global product launches.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen’s plans to expand its efforts in artificial intelligence; Tevogen’s ability to develop additional product candidates; Tevogen’s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is the purpose of Tevogen Bio's partnership with Databricks for TVGNW?
What are the two foundational models being developed for Tevogen's PredicTcell platform?
Who are the three pillars supporting Tevogen.AI's initiative?
What specific capabilities will PredicTcell enhance through the Databricks partnership?
